Clinical trials: Endometrial Carcinoma
Quality of Life, Cancer of Endometrium
FitEx for Endometrial Cancer Survivors
The purpose of this study is to determine whether a physical activity tracking program called FitEx would be useful to endometrial cancer survivors.
- Conditions
- Quality of Life, Cancer of Endometrium, Behavior, Health, Self Efficacy
- Trial name
- NCT05233059
- Testing
- FitEx, Weekly Yoga Sessions, Weekly Movement Sessions
- Where
- United States
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- Carilion Clinic
HER2-positive, Adenocarcinoma
CAR-macrophages for the Treatment of HER2 Overexpressing Solid Tumors
Phase 1, first-in-human, open label study of CAR macrophages in HER2 overexpressing solid tumors.
- Conditions
- HER2-positive, Adenocarcinoma, Bile Duct Cancer, Biliary Tract Cancer
- Trial name
- NCT04660929
- Testing
- CT-0508, Pembrolizumab
- Where
- 7 sites in United States
- Volunteers
- 48 people
- Sponsor
- Carisma Therapeutics Inc
Advanced Solid Tumor, Metastatic Solid Tumor
Study of Orally Administered MOMA-341 in Participants With Advanced or Metastatic Solid Tumors
This Phase 1, multi-center, open-label, dose escalation and dose optimization study is designed to assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PDx), and preliminary clinical activity of MOMA-341…
- Conditions
- Advanced Solid Tumor, Metastatic Solid Tumor, Endometrial Cancer, MSI-H Cancer
- Trial name
- NCT06974110
- Testing
- MOMA-341, Irinotecan, Immunotherapy
- Where
- 15 sites in United States, Australia
- Volunteers
- 132 people
- Sponsor
- MOMA Therapeutics
Platinum-resistant Ovarian Cancer, Testicular Cancer
A Phase 1 Study of CTIM-76 in Patients With Recurring Ovarian Cancer and Other Advanced Solid Tumors
This is a Phase 1a/1b, open-label, dose escalation and expansion study to evaluate the safety and efficacy of CTIM-76 (study drug), a CLDN6-directed T cell-engaging bispecific antibody , in participants with…
- Conditions
- Platinum-resistant Ovarian Cancer, Testicular Cancer, Endometrial Cancer
- Trial name
- NCT06515613
- Testing
- CTIM-76
- Where
- 15 sites in United States, United Kingdom
- Volunteers
- 156 people
- Sponsor
- Context Therapeutics Inc.
Endometrial Cancer
Combination Chemotherapy With or Without G-CSF in Treating Patients With Stage III, Stage IV, or Recurrent Endometrial Cancer
RATIONALE: Drugs used in chemotherapy use different ways to stop cancer cells from dividing so they stop growing or die. Combining more than one drug may kill more tumor cells.
- Trial name
- NCT00003691
- Testing
- filgrastim, cisplatin, doxorubicin hydrochloride
- Where
- 73 sites in United States, Canada
- Volunteers
- 240 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Carcinoma, Tumor Molecular Features Screening Model
Study and Transformation of Tumor Molecular Features Screening Model of Endometrial Carcinoma Surgical Approach
At present, endometrial carcinoma is one of the three most common malignant tumors in gynecology, and the incidence has been increasing year by year, causing a large health and economic burden to the society.
- Trial name
- NCT05894915
- Testing
- open surgery, laparoscopic surgery
- Volunteers
- 390 people
- Sponsor
- Peking University People's Hospital
Endometrial Cancer, Endometrial Neoplasms
Can Staging Magnetic Resonance Imaging (MRI) Features Prognosticate Patients Presenting With Endometrial Cancer?
Aim: Assess the value of MRI features in predicting prognosis in patients with endometrial cancer This study will examine the MRI features of women with confirmed endometrial cancer to see if textural features can prognosticate…
- Trial name
- NCT03543215
- Testing
- Radiomics: Analysis of textural features of imaging (MRI and Ultrasound)
- Where
- United Kingdom
- Volunteers
- 500 people
- Sponsor
- Imperial College London
Cancer of the Cervix, Cancer of the Endometrium
Real Time In-Vivo Dosimetry For Gynecologic Brachytherapy
This is an observational study. The purpose is to determine the feasibility of using a novel nano-scintillator fiber-optic dosimeter (nanoFOD) for the real time dosimetric monitoring of brachytherapy treatment.
- Trial name
- NCT02040155
- Testing
- Novel nano-scintillator fiber-optic dosimeter (nanoFOD)
- Where
- United States
- Volunteers
- 16 people
- Sponsor
- Duke University
Endometrial Cancer
BKM120 in Advanced, Metastatic, or Recurrent Endometrial Cancers
This is a phase II open label fixed dose study in subjects with advanced, metastatic, or refractory endometrial or ovarian, fallopian tube, or primary peritoneal cancer with PI3 kinase pathway activation as demonstrated by PIK3CA…
- Trial name
- BKM120 (NCT01550380)
- Testing
- BKM120
- Where
- United States
- Sponsor
- University of Utah
Lung Cancer, Gastric Cancer
INSPIRE: a Multi-Cancer Early Detection Study
This research constitutes a multi-centric, case-control designed investigation aimed at developing and implementing a blinded validation of a machine learning-powered, multi-cancer early detection model.
- Conditions
- Lung Cancer, Gastric Cancer, Liver Cancer, Colorectal Cancer
- Trial name
- INSPIRE (NCT06440018)
- Where
- China
- Volunteers
- 5,350 people
- Sponsor
- Singlera Genomics Inc.
Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma
VSV-hIFNbeta-NIS With or Without Ruxolitinib Phosphate in Treating Stage IV or Recurrent Endometrial Cancer
This phase I trial studies the side effects and best dose of vesicular stomatitis virus-human interferon beta-sodium iodide symporter (VSV-hIFNbeta-NIS) with or without ruxolitinib phosphate in treating patients with stage IV…
- Conditions
- Metastatic Endometrial Carcinoma, Recurrent Endometrial Adenocarcinoma, Recurrent Endometrial Carcinoma, Recurrent Endometrial Clear Cell Adenocarcinoma
- Trial name
- NCT03120624
- Testing
- Biopsy, Computed Tomography, Fluorine F 18 Tetrafluoroborate
- Where
- United States
- Volunteers
- 34 people
- Sponsor
- Mayo Clinic
Endometrial Carcinoma
UTOLA: UTerin OLAparib
This is a phase IIB, national, randomized, double-blinded, comparative, multi-center study, to assess the efficacy of Olaparib as maintenance after a platinum based chemotherapy in patients with Advanced or metastatic endometrial…
- Trial name
- UTOLA (NCT03745950)
- Testing
- Olaparib Oral Capsule
- Where
- 36 sites in France
- Volunteers
- 147 people
- Sponsor
- ARCAGY/ GINECO GROUP
Ovarian Cancer, Endometrial Cancer
Biomarkers for Gynecologic Cancer
A novel blood metabolic biomarker, AminoIndexTM (gynecological), was developed for gynecological cancers from over 400 Japanese patient's plasma free amino acid profiles (PFAAs) by a rapid and sensitive LC-MS (Liquid…
- Conditions
- Ovarian Cancer, Endometrial Cancer, Benign Gynecological Disease
- Trial name
- NCT02178462
- Where
- United States
- Volunteers
- 153 people, healthy volunteers welcome
- Sponsor
- Ajinomoto Co., Inc.
Malignant Neoplasms of Female Genital Organs
Feasibility of the NEXT Steps Weight Loss Intervention +/- Resistance Training for Endometrial Cancer Survivors: Effect on Lean Mass & Biomarkers
The goal of this research study is to learn if a home-based physical activity program is feasible and can help endometrial cancer survivors lose weight.
- Trial name
- NCT02774759
- Testing
- Accelerometer, Questionnaires, Fitness Test
- Where
- United States
- Volunteers
- 15 people
- Sponsor
- M.D. Anderson Cancer Center
Endometrial Disease
REM (Risk Of Endometrial Malignancy)
The purpose of this study was to obtain a predictive model to asses the Risk of Endometrial Malignancy (REM) in women with ultrasound endometrial abnormalities.
- Trial name
- REM (NCT01830192)
- Testing
- Training set, VERIFICATION SET
- Where
- Italy
- Volunteers
- 741 people
- Sponsor
- Campus Bio-Medico University
Endometriosis, Infertility
Harnessing the Disease Signatures From Endometrium and Menstrual Blood to Identify Avenues for the Treatment of Chronic Conditions Such as Endometriosis and Related Pathologies: This is an Observational Study Aimed at Shedding Light on Women's Health
Many women's health conditions have limited treatments available and poor outcomes, in part due to the lack of understanding of disease processes and lack of data available.
- Conditions
- Endometriosis, Infertility, Endometrial Cancer, Adenomyosis, Endometriosis
- Trial name
- CYCLE_ENDO (NCT06990971)
- Testing
- No Intervention: Observational Cohort
- Volunteers
- 200 people, healthy volunteers welcome
- Sponsor
- Cycle Therapeutics Ltd
Breast Cancer, Colo-rectal Cancer
The French E3N Prospective Cohort Study
The French E3N cohort was initiated in 1990 to investigate the risk factors associated with cancer and other major non-communicable diseases in women.
- Conditions
- Breast Cancer, Colo-rectal Cancer, Parkinson Disease, Asthma
- Trial name
- E3N (NCT03285230)
- Where
- France
- Volunteers
- 100,000 people, healthy volunteers welcome
- Sponsor
- Institut National de la Santé Et de la Recherche Médicale, France
Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma
Comparison of Two Combination Chemotherapy Regimens Plus Radiation Therapy in Treating Patients With Stage III or Stage IV Endometrial Cancer
Randomized phase III trial to compare the effectiveness of two combination chemotherapy regimens plus radiation therapy in treating patients who have stage III or stage IV endometrial cancer.
- Conditions
- Endometrial Adenocarcinoma, Endometrial Adenosquamous Carcinoma, Endometrial Clear Cell Adenocarcinoma, Endometrial Endometrioid Adenocarcinoma, Variant With Squamous Differentiation
- Trial name
- NCT00006011
- Testing
- Doxorubicin Hydrochloride, Cisplatin, Filgrastim
- Where
- United States
- Volunteers
- 659 people
- Sponsor
- Gynecologic Oncology Group
Endometrial Neoplasms, Atypical Endometrial Hyperplasia
GnRHa + Letrozole in Obese Progestin-insensitive Endometrial Cancer Patients
To investigate the efficacy of GnRHa plus letrozole in obese progestin-insensitive EEC patients.
- Conditions
- Endometrial Neoplasms, Atypical Endometrial Hyperplasia, Progesterone Resistance, Obesity
- Trial name
- NCT06379113
- Testing
- GnRH antagonist, Letrozole 2.5mg
- Where
- 2 sites in China
- Volunteers
- 29 people
- Sponsor
- Xiaojun Chen
Breast Cancer, Endometrial Cancer
A Study of LY353381 (Arzoxifene) for Patients Who Benefitted From This Drug in Other Oncology Trials and Wished to Continue Treatment
Patients who were previously enrolled on the LY353381 arm of any LY353381 oncology trial could enroll in this "roll-over" study if they had exhibited clinical benefit from treatment and wished to continue on treatment.
- Conditions
- Breast Cancer, Endometrial Cancer, Ovarian Cancer
- Trial name
- NCT00190697
- Testing
- arzoxifene
- Where
- United States
- Volunteers
- 70 people
- Sponsor
- Eli Lilly and Company
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.